Processa Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PCSA research report →
Companywww.processapharmaceuticals.com
Processa Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition.
- CEO
- George K. Ng
- IPO
- 2014
- Employees
- 10
- HQ
- Hanover, MD, US
Price Chart
Valuation
- Market Cap
- $6.09M
- P/E
- -0.50
- P/S
- 0.00
- P/B
- 2.78
- EV/EBITDA
- -0.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -281.30%
- ROIC
- -569.59%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-13,563,834 · -14.46%
- EPS
- $-10.36 · 89.29%
- Op Income
- $-13,988,505
- FCF YoY
- -1.22%
Performance & Tape
- 52W High
- $19.63
- 52W Low
- $1.76
- 50D MA
- $2.77
- 200D MA
- $4.61
- Beta
- 1.01
- Avg Volume
- 67.42K
Get TickerSpark's AI analysis on PCSA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Ng George K | buy | 1,843 |
| May 15, 26 | Young David | buy | 1,545 |
| May 15, 26 | Lin Patrick | buy | 1,369 |
| May 15, 26 | Guy Wendy | buy | 1,583 |
| May 15, 26 | SKIBSTED RUSSELL | buy | 1,984 |
| Apr 30, 26 | Bigora Sian | buy | 1,971 |
| Apr 30, 26 | Young David | buy | 1,706 |
| Apr 30, 26 | SKIBSTED RUSSELL | buy | 2,190 |
| Apr 30, 26 | Ng George K | buy | 2,034 |
| Apr 30, 26 | Lin Patrick | buy | 1,511 |
Our PCSA Coverage
We haven't published any research on PCSA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PCSA Report →